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ge are honored to provide readers of the Journal with this
eview of major scientific work in the field of Interventional
ardiology in 2009. In addition, we have included late-
reaking trials presented at the American College of Car-
iology, Transcatheter Cardiovascular Therapeutics, Euro-
ean Society of Cardiology, and American Heart
ssociation conferences. We hope that this article will
rovide a broad overview of the field for general cardiolo-
ists, as well as a framework for more detailed study for
hose with a specific interest in interventional cardiology.
ocused Update
focused update of American College of Cardiology/
merican Heart Association/Society for Cardiovascular
ngiography and Interventions guidelines for ST-segment
levation myocardial infarction (STEMI) and percutaneous
oronary intervention (PCI) was published in 2009 (1).
mportant changes in this update are summarized in Table
. Readers are encouraged to examine this document in
etail.
cute Myocardial Infarction
rimary PCI. In a meta-analysis of 23 randomized and 32
bservational studies, Huynh et al. (2) reported significant
mprovement in mortality, stroke, and reinfarction compar-
ng primary PCI with thrombolysis.
CI after thrombolysis. Although the role of facilitated
CI remains controversial, many studies suggest it is supe-
ior to thrombolysis alone. The TRANSFER-AMI (Trial
f Routine Angioplasty and Stenting after Fibrinolysis to
nhance Reperfusion in Acute Myocardial Infarction) study
nrolled 1,059 high-risk STEMI patients treated with lytics
t non-PCI centers and randomized them to immediate
ransfer for PCI within 6 h versus delayed catheterization
3). Immediate transfer for PCI was associated with reduced
ajor adverse cardiac event (MACE) (11.0% vs. 17.2%; p
rom *William Beaumont Hospital, Royal Oak, Michigan, and the †University of
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herapeutics, Sanofi-Aventis, and Svelte Medical Systems. Dr. O’Neill is a consultante
or Medtronic and Byrne Healthcare Inc.
Manuscript received December 28, 2009, accepted February 2, 2010..004) with no increase in major bleeding. A Norwegian
tudy (4) randomized 266 patients treated with tenecteplase
n remote hospitals (90-min transfer times) to immediate
ransfer for PCI versus conservative care. The group ran-
omized to transfer for PCI had reduced ischemia at 30
ays and an improved composite of death, myocardial
nfarction (MI), or stroke at 12 months. Similarly, the
-year follow-up of the REACT (Rescue Angioplasty
ersus Conservative Management or Repeat Thrombolysis)
rial found that rescue PCI after failed thrombolysis (5)
mproved event-free survival compared with conservative
are (81.5% vs. 67.5%; p  0.004).
acilitated PCI. Conversely, pharmacologic facilitation is
f no benefit compared with primary PCI. The FINESSE
Facilitated Intervention with Enhanced Reperfusion Speed
o Stop Events) trial reported that thrombolytic- or
bciximab-mediated facilitation, or both, before PCI was
ssociated with higher bleeding but no short-term clinical
dvantage compared with primary PCI. However, at 1 year,
trend for lower mortality was suggested in facilitated
atients with anterior MI (6.5% vs. 9.9%; p  0.093) (6) or
n high-risk patients who sought treatment at a remote
ospital within the first few hours from symptom onset (7).
rug-eluting stents (DES). A meta-analysis of 13 trials
andomizing 7352 patients to DES versus bare-metal stents
BMS) for acute myocardial infarction (AMI) found re-
uced target vessel revascularization (TVR) (relative risk:
.44; 95% confidence interval: 0.35 to 0.55), but no in-
reased risk of death, MI, or stent thrombosis (ST) (8).
ong-term follow-up of randomized trials suggest contin-
ed safety and efficacy of DES compared with BMS (9–13).
recently reported randomized trial (n  466) confirmed
hat the sirolimus-eluting stent (SES) was superior to the
MS at improving restenosis and TVR (14). An endothelial
rogenitor cell capture stent had similar restenosis rates but
lightly higher ST compared with BMS in a small trial (15).
hrombectomy. In 2 small randomized trials, aspiration
hrombectomy during primary PCI was associated with
igher rate of ST-segment resolution and myocardial blush
rade of 2 or more (16,17). In a substudy of 1 trial, patients
ith anterior STEMI treated with thrombectomy had less
icrovascular obstruction and smaller infarct on cardiac
RI (16). In the other study, the thrombus aspiration
roup had a higher ejection fraction (EF) and less remod-
ling at 6 months (17).
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May 18, 2010:2272–86 Year in Interventional CardiologyIn contrast to these findings, a randomized trial using
roximal embolic protection (Proxis, St. Jude Medical, St.
aul, Minnesota) found no difference in ST-segment resolu-
ion at 60 min in patients treated with the protection device
18). However, there did seem to be a higher rate of immediate
omplete ST-segment resolution in the Proxis group.
djunctive agents. Several studies in 2009 investigated
ovel pharmacologic or mechanical therapies to limit myo-
ardial injury in AMI. In patients with anterior wall
TEMI of 6 h, Stone et al. (19) demonstrated that a
0-minute infusion of supersaturated oxygen into the left
nterior descending coronary artery (LAD) after reperfusion
ignificantly decreased infarct size compared with controls
18.5% vs. 25% of the left ventricle [LV]; p  0.02). Sezer
t al. (20) found that intracoronary streptokinase adminis-
ered immediately after reperfusion reduced infarct size and
V volumes at 6 months. In a small randomized trial,
igh-dose erythropoietin administered during primary PCI
with repeat doses at 24 and 48 h) had no effect on
onvalescent LV EF assessed by magnetic resonance imag-
ng (MRI) at 6 months (21). Fokkema et al. (22) random-
zed 448 patients to 2 doses of intracoronary adenosine (120
g) or placebo after thrombectomy. The primary end point,
esidual ST-segment elevation at 30 to 60 min after PCI,
as not significantly different between groups. In another
rial (n  234), intravenous FX06 (a naturally occurring
eptide derived from human fibrin) reduced necrotic core
8% on MRI at day 5, but there was no difference in scar
ize at 4 months (23).
ransfusion. There has been increased attention to the
mpact of blood transfusion after PCI. Three studies in
009 identified a strong relationship between blood trans-
usion after primary PCI and increased risk of short- and
ong-term mortality (24–26). Whether blood transfusion
lays a causative role in these adverse outcomes or is simply
marker of increased risk remains unclear. Nonetheless,
hese data should serve as a call to re-examine the indica-
ions and optimal threshold for transfusion in anemic
009 Focused Update on STEMI and PCI: Key ChangesTable 1 2009 Focused Update on STEMI and PCI: Key Change
STEMI Update
Usefulness of cath lab (up front) glycoprotein IIb IIIa antagonists is uncertain (Clas
A loading dose of thienopyridine should be given as soon as possible and continu
undergoing DES placement (Class IIb).
Prasugrel should be avoided in patients with prior history of stroke or TIA (Class II
In patients pretreated with aspirin and thienopyridine (unfractionated heparin),
bleeding (Class IIa).
Both high-risk (Class IIa) and low-risk (Class IIb) patients who receive fibrinolytic th
It is reasonable to use DES as an alternative to BMS in STEMI patients.
PCI Update
In patients with chronic kidney disease, either iso-osmolar or low-osmolar contras
Stenting of the left main may be considered as an alternative to CABG when anat
dapted from Kushner et al. (1).
BMS  bare-metal stent(s); CABG  coronary artery bypass graft; DES  drug-eluting stent(s)
IA  transient ischemic attack.atients after PCI. mutcomes. Two studies evaluated the relationship between
olume and primary PCI outcomes. Srinivas et al. (27)
tudied 7,321 AMI patients in the New York State PCI
egistry. Risk-adjusted in-hospital mortality was highest
or low-volume operators (10/year) in low-volume hospi-
als (50/year) compared with high-volume physicians in
igh-volume centers. In another analysis, Kumbhani et al.
28) found high-volume primary PCI centers (70/year)
ad shorter door-to-balloon times, but similar in-hospital
ortality to medium-volume (36 to 70/year) and low-
olume (36/year) centers.
ardiogenic shock. Lim et al. (29) evaluated the outcomes
f PCI for cardiogenic shock in 45 elderly patients (75
ears of age). Rates of stenting (86.7%) and IIb/IIIa use
68.9%) were much higher than in prior shock studies.
n-hospital and 1-year survival was similar to that of
ounger patients (75 years of age). These data suggest that
ercutaneous revascularization is reasonable in carefully
elected elderly patients with shock complicating AMI.
ehta et al. (30) examined Thrombolysis In Myocardial
nfarction (TIMI) flow after PCI in shock patients and
ound that patients with TIMI flow grade 3 had a
ubstantially higher mortality (63% vs. 27%) than patients
ith TIMI flow grade 3.
ell therapy. Very small embryonic-like stem cells have
een found in peripheral blood samples of AMI patients,
ut not in normal volunteers (31), suggesting that these
ay play a role in cardiac and endothelial repair. Intra-
oronary infusion of bone marrow-derived stem cells was
hown to improve regional myocardial function (32) and
lobal ejection fraction (33) in prospective, randomized
rials. A nonrandomized observational study also sug-
ested improved LV function, exercise capacity, and
ortality in AMI patients treated with intracoronary
tem cells (34).
cute Coronary Syndromes (ACS)
iming of intervention. Although the efficacy of invasive
1 year (Class I), with consideration of longer duration (15 months) in patients
din may be used (Class I) and is reasonable in STEMI patients at high risk of
at a non-PCI faculty should be transferred to a PCI-capable lab.
be used (Class I).
nd clinical conditions are favorable for PCI (Class IIb).
percutaneous coronary intervention; STEMI  stent thrombosis elevation myocardial infarction;s
s IIb).
ed for
I).
bivaliru
erapy
t may
omic aanagement of ACS is well established, optimal timing of
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Year in Interventional Cardiology May 18, 2010:2272–86ntervention and adjunctive pharmacotherapy is not settled.
he year 2009 brought numerous trials in this area. Mehta
t al. (35) randomized 3,031 patients with ACS to early
outine invasive (24 h from admission) versus delayed
36 h from admission) intervention. The trial found no
ifference in 6-month death/MI/stroke (9.6% vs. 11.3%; p
0.15) for early versus delayed intervention. For patients in
he highest tertile of risk (GRACE [Global Registry of
cute Coronary Events] score 140), outcome was im-
roved with early intervention (13.9% vs. 21%; p  0.006).
second trial, ABOARD (Angioplasty to Blunt the Rise of
roponin in ACS), evaluated the efficacy of immediate
ersus delayed intervention in blunting troponin increase
36). Neither peak troponin level nor death/MI/TVR at 1
onth was lessened by immediate intervention. Finally,
iugliano et al. (37) evaluated early versus delayed provi-
ional use of eptifibatide in 9,492 patients with ACS who
nderwent PCI. No difference in death or MI occurred, and
arly eptifibatide use resulted in more bleeding and a higher
eed for transfusion (8.6% vs. 6.7%; p  0.001). Taken
ogether, these trials suggest equivalent efficacy for an
mmediate or delayed PCI strategy in patients with ACS,
ith perhaps a need for early intervention in high-risk
atients.
utcomes. Several substudies of the ACUITY (Acute
atheterization and Urgent Intervention Triage Strategy)
rial were reported. Nikolsky et al. (38) highlighted the
atastrophic prognostic implications of gastrointestinal
leeding (GIB) after PCI. One-year mortality was greater
21.9% vs. 3.9%; p  0.0001) for the 1.3% of patients who
ad GIB. In addition, composite ischemia and acute ST was
ignificantly higher (5.8% vs. 2.4%; p  0.009). Risk factors
or GIB included age, smoking status, and baseline anemia.
ehran et al. (39) assessed the prognostic impact of chronic
idney disease. Patients with creatinine clearance of 60
l/min had a significantly higher 1-year mortality (7.9% vs.
.8%; p  0.001) and higher rates of ischemia and GIB.
ivalirudin appeared to lessen the risk of bleeding but did
ot influence 1-year mortality. Lopes et al. (40) evaluated
he impact of age and found that patients older than 75
ears had significantly worse outcomes. These patients were
ore likely to be female, to have lower weight, and to have
ower creatinine clearance. Major bleeding was lessened
ith bivalirudin in these elderly patients (1.7% vs. 3.6%; p
.05) compared with heparin plus glycoprotein IIb/IIIa
nhibitors. Finally, Prasad et al. (41) examined the prognos-
ic impact of periprocedural or spontaneous MI occurring
fter PCI. PCI-related MI occurred in 6% of patients, and
uring follow-up, spontaneous MI occurred in 2.6% of
atients. One-year mortality was 16% after spontaneous
I, 6% after periprocedural MI, and 2.6% when no MI
ccurred (p  0.0001). Although spontaneous MI did
orsen prognosis independently, periprocedural MI did not
o so when baseline variable differences were accounted forn linear regression analysis. slective PCI
evascularization criteria. Early in 2009, an important
ocument summarizing appropriateness criteria for coro-
ary revascularization was published (42). In brief, these
riteria were developed by scoring 180 prototypical clinical
cenarios on a scale of 1 to 9 as inappropriate (1 through 3),
ncertain (4 through 6), or appropriate (7 through 9). Key
omponents of the criteria include patient clinical status,
evel of medical therapy, stress testing findings, and coro-
ary anatomic features. Although these criteria were devel-
ped to assist clinicians, health care facilities, payors, and
atients, it is important to emphasize that they are not
ntended to be a substitute for clinical judgment and
xperience. Nonetheless, the criteria are likely to be studied
losely by payors, especially in the current economic climate.
eaders are encouraged to review the article in detail.
edical therapy. The BARI 2D (Bypass Angioplasty
evascularization Investigation 2 Diabetes) (43) trial pro-
ided further debate in the interventional community, but
verall adds to the body of evidence that medical therapy is
n excellent initial strategy in patients with stable coronary
isease. A total of 2,368 patients with type 2 diabetes were
andomized to intensive medical therapy or revasculariza-
ion (PCI or coronary artery bypass graft surgery [CABG])
ith medical therapy. At the 5-year follow-up, there was no
ifference in the rate of death or the composite of death/
I/stroke. Of note, however, 42% of patients in the
edical therapy arm crossed over to revascularization. Ad-
itionally, patients in the revascularization arm who under-
ent CABG had fewer adverse events at follow-up com-
ared with medically treated patients, driven largely by a
educed incidence of MI. A meta-analysis by Trikalinos et
l. (44) reaffirmed prior observations that PCI does not
mpact the rate of death or MI in patients with stable
isease.
AD disease. Thiele et al. (45) presented results of a
andomized trial of SES versus minimally invasive coronary
rtery bypass surgery for isolated proximal LAD disease. At
2 months, TVR was higher for the SES group, but overall,
ACE was identical in each group (7.7%).
ultivessel disease. Results of the SYNTAX (Synergy
etween Percutaneous Coronary Intervention with Taxus
nd Cardiac Surgery) trial were published in 2009. One
housand ninety-five patients with 3-vessel or left main disease
ere randomized to CABG (n 549) or multivessel PCI with
he Taxus DES (n  546) (46). At 1 year, there was a higher
ncidence of MACE (death, MI, stroke, repeat revasculariza-
ion) in the PCI group compared with the CABG group
17.8% vs. 12.4%; p  0.002). This was driven largely by a
igher need for TVR in the PCI group, however, there was a
ower risk of stroke (0.6% vs. 2.2%; p 0.003). The difference
n MACE was greatest in patients with more complex coro-
ary disease (SYNTAX score, 33).
In an observational study of 3,720 patients with multives-el disease, patients treated with DES had a higher 3-year
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May 18, 2010:2272–86 Year in Interventional Cardiologyate of TVR, death, and MI (47). In contrast, Hlatky et al.
48) found no difference in long-term survival in a meta-
nalysis of 7,812 patients treated with PCI (37% BMS; 63%
ercutaneous transluminal coronary angioplasty) versus
ABG; however, in patients with diabetes, mortality was
ower in the CABG group.
eft main disease. There is a growing body of evidence to
upport PCI for unprotected left main coronary artery
isease. Several observational studies provided long-term
utcome data with BMS and DES (49–52) (Table 2). In
ggregate, DES seemed to reduce risk of TVR and MACE.
mong patients with distal bifurcation disease, 2 observa-
ional studies demonstrated higher rates of adverse events
hen side-branch stenting was performed compared with
ain vessel stenting alone (51,52). Two studies (1 nonran-
omized, 1 randomized) compared SES with paclitaxel-
luting stents (PES) and found similar outcomes between
tent types (53,54). Park et al. (55) studied the role of
ntravascular ultrasound guidance in unprotected left main
oronary artery stenting. In a propensity-matched analysis,
atients receiving a DES had significantly lower 3-year
ortality with intravascular ultrasound guidance versus
ngiography alone (4.7% vs. 16.0%; p 0.048). For patients
ith DES restenosis, Sheiban et al. (56) found that most
ases can be treated favorably with PCI. Palmerini et al. (57)
tudied the timing of cardiac events after unprotected left
ain coronary artery stenting (73% DES). In patients
eceiving dual antiplatelet therapy, the highest risk of events
as in the first 6 months after PCI, especially among
atients who initially had ACS. After clopidogrel discon-
inuation, the highest risk period was the first 90 days after
topping therapy.
ractional flow reserve guidance. The FAME (Fractional
low Reserve versus Angiography for Multivessel Evalua-
ion) study was an important highlight of the year (58). One
housand five patients with multivessel disease undergoing
CI were randomized to stenting guided by angiography
lone or guided by fractional flow reserve (FFR) measure-
tudies of Stenting for Unprotected Left Main Coronary Disease inTable 2 Studies of Stenting for Unprotected Left Main Coronar
Study
(First Author, Ref #) n Country (yrs) Stent Type
BMS vs. DES
Buszman et al. (49) 252 Poland, 1997–2008 158 BMS, 94 DES
Kim et al. (50) 1,217 Korea, 2000–2006 353 BMS, 864 DES
DES
Toyofuku et al. (51) 476 Japan, 2004–2006 476 SES
Vaquerizo et al. (52) 291 France, 2003–2005 291 PES
SES vs. PES
Lee et al. (53) 858 Korea, 2000–2006 Nonrandomized; 669 SES, 18
Mehilli et al. (54) 607 Germany, 2005–2007 Randomized; 305 SES, 302 PR  hazard ratio; MACE  major adverse cardiac event; MI  myocardial infarction; PES  paclita
evascularization; TVR  target vessel revascularization; other abbreviations as in Table 1.ents (stent indicated if FFR0.8). Fewer stents were used
n the FFR group (1.9 vs. 2.7; p  0.001). Importantly, the
rimary end point (death, MI, and TVR at 1 year) was
ignificantly lower in the FFR group (13.2% vs. 18.3%; p 
.02) compared with the angiography group, strongly sup-
orting routine use of FFR in multivessel intervention.
igh-risk PCI. There are few data regarding the optimal
anagement of high-risk patients undergoing PCI. The
CIS (Balloon Pump-Assisted Coronary Intervention
tudy) (the first randomized trial in this patient group)
andomized 301 high-risk patients (EF 30%; jeopardy
core 8) to elective versus provisional intra-aortic balloon
ump (59). Twelve percent of patients required bailout
ntra-aortic balloon pump. There was no significant differ-
nce in MACE in either group at 30 days. This important
tudy suggests that many patients with LV dysfunction can
e treated safely without routine hemodynamic support, but
id not specifically address what support strategy to use in
ery–high-risk patients in whom periprocedural circulatory
upport is considered essential. In other studies, use of the
mpella 2.5 device (Abiomed, Danvers, Massachusetts) was
ound to be safe and feasible in high-risk patients (60,61).
ifurcations. Recent studies have demonstrated that a
ingle main vessel stent strategy is the preferred technique in
oronary bifurcations. In the CACTUS (Coronary Bifurca-
ions: Application of the Crushing Technique Using
irolimus-Eluting Stents) study, 350 patients were random-
zed to elective crush stenting versus stenting of the main
essel only with provisional side-branch T-stenting (62). At
months, the incidence of angiographic restenosis (main
ranch and side branch) and MACE was similar in the 2
roups. In a meta-analysis of 6 trials comparing single- or
ouble-stent strategies, a higher incidence of periprocedural
I was observed with double stenting (63).
Kissing balloon dilatation often is used in main vessel
tenting to optimize the side branch. In the Nordic-Baltic
ifurcation Study III (64), 477 patients with successful
ain vessel stenting (and side branch 2.25 mm) were
ease in 2009
Follow-Up (yrs) Main Findings
5/10 Survival at 5/10 yrs, 78.1% and 68.9%; lower MACE with
DES vs. BMS
3 DES2TLR (HR, 0.40; p  0.03); no difference death/MI
3 Lower rate of TVR for ostial/shaft vs. distal lesions; for distal
lesions,2TLR and MACE with main-branch stenting alone vs.
2-stent technique
2 MACE, 15.8%; ST, 3.8%; higher-risk ST with side-branch stenting
3 No difference outcomes SES vs. PES
1 Comparable angiographic and clinical outcomes between SES
and PES2009y Dis
9 PES
ESxel eluting stent; SES  sirolimus-eluting stent; ST  stent thrombosis; TLR  target lesion
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Year in Interventional Cardiology May 18, 2010:2272–86andomized to final kissing balloon after dilatation or no
ost-dilation. At 6 months, there was no difference in
linical outcome between groups, suggesting that routine
issing balloon after dilatation is not necessary.
Among patients undergoing a planned 2-stent strategy,
he Nordic Stent Technique Study demonstrated similar
linical outcomes between the crush and culotte techniques
using a SES); however, angiographic restenosis in the side
ranch was lower with culotte stenting (65).
The DIVERGE (Drug-Eluting Stent Intervention for
reating Side Branches Effectively) study evaluated the
xxess (Devax Inc., Lake Forest, California) biolimus
9-eluting in 302 patients (66). At 9 months, there was a
ow rate of restenosis (3.6% parent vessel; 4.3% side branch)
nd MACE (7.7%) with this novel self-expanding stent.
hronic occlusion. Rathore et al. (67,68) reported out-
omes in 904 patients with undergoing PCI for chronic
oronary artery occlusion at a single center. With modern
uidewire techniques, procedural success was 86.2%. Ret-
ograde crossing was used in 7.2% of patients with a 65.6%
uccess rate. Overall, a very low rate of in-hospital MACE
1.9%) was observed in this highly experienced center.
utcomes. In 2009, there were several interesting articles
ddressing outcomes after PCI. Resnic and Welt (69)
rovided a report on the potential negative impact of public
eporting of PCI outcomes. In Massachusetts, a 47%
ecline in use of PCI for cardiogenic shock was observed
fter mandatory reporting was initiated in 2003. Khattab et
l. (70) examined DES outcomes and hospital volume in 51
erman centers. High-volume (400 PCIs/year) centers
ad a significantly lower incidence of death and MI com-
ared with intermediate- and low-volume centers. Hannan
t al. (71) studied ad hoc procedures in New York State
rom 2003 through 2005 (83% PCI ad hoc). Ad hoc
atients had lower baseline clinical risk. There was no
ifference in in-hospital mortality; however, ad hoc patients
ad lower 3-year mortality. Ryan et al. (72) examined health
are costs in Medicare patients after the introduction of
ES. Although total cardiovascular cost per revascularized
atient decreased by approximately $1,680 after the introduc-
ion of DES, overall health care costs were significantly higher
ecause of greater use of revascularization procedures.
ell therapy. In a 50-patient randomized double-blind
rial, van Ramhorst et al. (73) evaluated intramyocardial
njection of autologous bone marrow-derived mononuclear
ells in patients with chronic myocardial ischemia. At 3
onths, intramyocardial injection was associated with a
ignificant improvement in myocardial perfusion, angina,
nd EF compared with placebo.
ES
ES healing. An angiographic study of 1,197 patients
eceiving DES found that acquired aneurysms were rare, but
ccurred more frequently when a DES was implanted
uring AMI (74). Similarly, Gonzalo et al. (75) reported Shat primary PCI patients had higher frequency of stent
alapposition and uncovered struts assessed by optical
oherence tomography 6 months after DES, compared with
lective DES patients. The type of stent also influences
ealing with angioscopic incidence of less neointimal cov-
rage and more thrombus with PES compared with SES
76), and more restenosis but better endothelial function
ith BMS and zotarolimus-eluting stent (ZES) compared
ith SES (77).
ES thrombosis. DES fracture is rarely reported in
linical series, but an autopsy study reported fracture in
1 (29%) of 177 stented lesions (78). Predictors of stent
racture included longer, overlapping stents and use of
ES.
Late ST after DES continues to be of interest to
ardiologists. A literature review of 161 ST cases found that
8% were not taking dual antiplatelet therapy (79). If both
spirin and clopidogrel were stopped, the median time to
T was 7 days; whereas if the aspirin was continued, ST
ccurred 122 days after clopidogrel was stopped. Likewise,
imura et al. (80) reported in a registry of 10,000 SES-
reated patients that discontinuation of both aspirin and
lopidogrel greatly increased ST, but if aspirin was contin-
ed, thrombosis was so low that there was no apparent
enefit of long-term clopidogrel. However, in a 7,500-
atient Taxus registry, Lasala et al. (81) found that discon-
inuation of thienopyridine was associated with very late
1 year) stent thrombosis. Similarly, a Dutch registry (82)
f 437 patients with ST found a strong correlation between
ate ST and discontinuing clopidogrel at 6 months (hazard
atio: 5.9; 95% confidence interval: 1.7 to 19.8). This
egistry also reported high rates of death, MI, and recurrent
T, with poor outcomes occurring more frequently in
atients with low EF, diabetes, complex lesions, long stent
ength, TIMI flow grade3, and implantation of additional
tents for treatment of the ST (83). Other studies have
hown that lack of pretreatment thienopyridine (84) or
lopidogrel hyporesponsiveness (85) contribute to the risk of
ES thrombosis.
ate outcomes. Several studies with up to 5 years of
ollow-up report lower TVR with first-generation DES
ompared with BMS with similar rates of death and MI
86 –90). However, consistent with some of the random-
zed trial data, 1 large national registry suggested that
ES had an increased risk of ST and MI compared to SES or
MS (91).
Second-generation DES may have a better long-term
afety profile compared with PES or SES. The SPIRIT III
Clinical Evaluation of the Xience V Everolimus-Eluting
oronary Stent System in the Treatment of Patients with
e novo Native Coronary Artery Lesions) trial found
mproved event-free survival at 2 years with trends for
educed ST comparing Xience V (Abbott Vascular, Santa
lara, California) EES with Taxus (Boston Scientific,
atick, Massachusetts) PES (92). The larger (n  3,687)
PIRIT IV trial confirmed that Xience was superior to
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May 18, 2010:2272–86 Year in Interventional Cardiologyaxus Express with significant improvement in event-free
urvival and ST (93). Moreover, the COMPARE (Second-
eneration everolimus-eluting and paciltaxel-eluting stents
n real-life practice) trial (n  1,800) found significant
eductions in TVR, MI, and ST with Xience compared with
he new Taxus Liberté (94). Finally, the ZEST (Compar-
son of the Efficacy and Safety of Zotarolimus-Eluting Stent
ersus Sirolimus-Eluting Stent and Paciltaxel-Eluting Stent
or Coronary Lesions) trial randomized 2,640 patients to
ES, SES, or Taxus Liberté (Boston Scientific) and found
hat Cypher SES was superior to both ZES and PES at
educing TVR and stent thrombosis (95).
linical and anatomic subsets. A small randomized trial
eported lower rates of restenosis when SVG lesions were
reated with PES compared with BMS (96). In another
mall randomized trial, a strategy of PES implantation for
oderate vein graft lesions seemed to improve outcome
ompared with medical therapy (97). A registry of SES in
hronic total occlusions showed safety and reduced resteno-
is (compared with historical controls with BMS) (98). Two
arge registries demonstrated that off-label use of DES had
imilar safety compared with BMS, yet was associated with
ower TVR (99,100). A Taxus registry suggested similar
ngiographic and clinical outcomes between diabetics and
ondiabetics (101). Among diabetics, ZES seems to be
nferior to other DES (102,103). However, ZES may
erform well in bifurcation lesions, given that side-branch
cclusion (and periprocedural MI) occurred less frequently
ith ZES compared with PES (104).
The best management of DES restenosis is uncertain.
SAR-DESIRE 2 (Intracoronary Stenting and Angio-
raphic Restenosis: Drug-Eluting Stents for In-Stent Re-
tenosis) randomized 450 patients with SES restenosis to
eceive PCI with additional SES versus PES (105). They
ound repeat restenosis (19.0% vs. 20.6%) and clinical events
ere similar, suggesting no advantage in choosing a differ-
nt stent for treatment of DES restenosis.
ew Stents and Balloons
rug-coated balloons. It is unknown whether adverse
vents after DES placement are the result of the drug,
olymer, or stent itself. New technologies on the horizon
nclude drug-eluting balloons, polymer-free stents, and
ioabsorbable polymer and stents. Unverdorben et al. (106)
andomized 131 patients with in-stent restenosis to treat-
ent with a paclitaxel-eluting balloon (PEB) versus PES. A
ignificant reduction in late loss was observed in the PEB
roup with a trend for reduced restenosis, TVR, and
ACE compared with PES. Similarly, Herdeg et al. (107)
eported that local delivery of fluid paclitaxel after BMS
lacement reduced neointimal proliferation and MACE
ompared with BMS alone. Conversely, Hamm (108)
andomized 637 patients to PEB and BMS versus Cypher
ES and found that the PEB and BMS combination pesulted in significant increases in stent thrombosis, MI,
estenosis, and TVR.
ew drugs, polymers, and stents. A DES using the
nti-inflammatory agent pimecrolimus was found to be
nferior to BMS (109), PES (110), or dual elution of both
rugs. Conversely, a biolimus-eluting stent with bioresorb-
ble polymer was superior to PES at reducing late loss and
estenosis (111). In a randomized trial of 1007 patients,
yrne et al. (112) found the ZES (Endeavor, Medtronic)
tent was inferior (more late loss, restenosis, and TVR) to
ither SES or a novel dual-DES (polymer-free rapamycin
nd probucol-eluting stent). A Chinese registry (113) re-
orted satisfactory results using an SES with biodegradable
olymer; however, late loss was higher (0.21  0.35 mm)
han previously reported for the durable polymer SES.
Polymer-free rapamycin stents had improved neointimal
overage at 3 months (114), compared with durable poly-
er. Byrne et al. (115) randomized 2,603 patients to a
apamycin-eluting stent with biodegradable polymer to
urable polymer stents (Cypher and Xience) and found
imilar angiographic and clinical outcomes. Therefore, to
ate, it seems that biodegradable polymers do not offer an
dvantage.
Other studies evaluated novel stent coatings designed to
ddress the limitations of current stent platforms. Promising
rst-in-man results were seen with a nanothin-microporous
ydroxyapatite surface coating impregnated with a polymer-
ree low dose of sirolimus (116), as well as a nanothin
olyzene-F–coated stent (117).
Bioabsorbable stents have been evaluated in small series
nd seem to have less scaffolding effect and decreased lumen
ize at 6 months; however, the long-term effects are favor-
ble (118,119).
harmacotherapy
lopidogrel. Because clopidogrel does not have antiplate-
et effect until it is converted by hepatic cytochrome P-450,
ts antiplatelet effect can be quite variable. There may be
enetic predisposition to reduced clopidogrel responsiveness
nd higher MACE in patients with cytochrome P-450
olymorphisms (120–122). Moreover, drugs that affect
ytochrome P-450 (particularly the proton pump inhibitor
meprazole) have been shown to reduce clopidogrel effec-
iveness and increase ischemic complications (123,124).
espite a Food and Drug Administration (FDA) advisory
uggesting caution, other studies reported that the com-
ined use of clopidogrel and omeprazole is safe (125,126)
nd provide reassurance. However, numerous investigators
ave shown a higher risk of ST in patients with clopidogrel
yporesponsiveness (85), and these patients may benefit
rom more potent antiplatelet agents such as a glycoprotein
Ib/IIIa inhibitor (127,128).
Higher-dose clopidogrel also may improve clinical out-
omes. In STEMI patients undergoing primary PCI,
retreatment with 600 mg clopidogrel was associated
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Year in Interventional Cardiology May 18, 2010:2272–86ith a reduced rate of ST, MI, and death compared with
300-mg dose (129). The CURRENT OASIS-7 (Clo-
idogrel Optimal Loading Dose Usage to Reduce Recur-
ent Events/Optimal Antiplatelet Strategy for Interven-
ions) trial randomized 17,000 ACS patients undergoing
CI to double dosing (600 mg load and 150 mg/day for
days followed by 75 mg/day) versus conventional dosing
130). The double-dose group had significant reductions
n death, MI, and stroke and a 42% decrease in ST (Fig.
). At our institution, we have used 600-mg loading
oses for several years, but based on this study, we are
ow giving 150 mg clopidogrel for the first 7 days in all
CS and STEMI patients.
Although concern still exists regarding pretreatment with
lopidogrel in ACS patients who ultimately may require
ABG, the ACUITY trial reported a significant reduction
n ischemic events in patients who received clopidogrel
efore CABG (131).
rasugrel. Results of the 3,534 STEMI patients within the
RITON–TIMI 38 (Trial to Assess Improvement in Ther-
peutic Outcomes by Optimizing Platelet Inhibition with
rasugrel–Thrombolysis in Myocardial Infarction 38) trial
ere published in 2009 (132). Patients were randomized to
eceive prasugrel (60 mg loading, 10 mg maintenance) or
lopidogrel (300 mg loading, 75 mg daily). Only 27%
atients received medication before PCI. At 30 days,
atients treated with prasugrel had a significantly lower
ncidence of the primary end point, death/MI/stroke (6.5%
s. 9.5%; p 0.0017), and ST (1.2% vs. 2.4%; p  0.0084),
ithout an increased risk of major bleeding. Further studies
re needed to determine if prasugrel is beneficial compared
o patients receiving higher clopidogrel dosing for STEMI.
n a separate analysis from the trial, prasugrel was beneficial
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Figure 1 Antiplatelet Agents Shown to Reduce Stent Thrombos
Bar graph showing incidence of stent thrombosis (ST) in studies comparing convenn ACS patients regardless of whether a glycoprotein
Ib/IIIa inhibitor was used (133). Additionally, prasugrel
as found to reduce both periprocedural and spontaneous
I (134).
icagrelor. Ticagrelor is an oral reversible ADP inhibitor
hat has more rapid and consistent platelet inhibition than
lopidogrel. The PLATO (Platelet Inhibition and Patient
utcomes) trial randomized 18,624 ACS patients to receive
icagrelor or clopidogrel (135). The overall trial demon-
trated a significant reduction in death/MI/stroke at 12
onths with ticagrelor, without an increase in major bleed-
ng. Results of 2 planned substudies also were presented
136,137). In patients with STEMI (n  8,430) and ACS
atients with a planned invasive strategy (n  13,408),
icagrelor was associated with significant reductions in
eath, MI, and ST. This represents an important step
orward in oral antiplatelet therapy, and based on these
esults, ticagrelor likely will become the standard of care for
CS patients.
angrelor. Intravenous cangrelor, a rapid-acting, revers-
ble adenosine diphosphate (ADP) receptor antagonist, was
valuated in 2 large randomized trials (138,139). In one
rial, clopidogrel 600 mg was given before PCI, and in the
ther trial, clopidogrel 600 mg was given after PCI. In both
tudies, cangrelor failed to improve the incidence of death/
I/ischemia-driven TVR at 48 h, but there was a lower
ncidence of ST in patients who were not pretreated with
lopidogrel (138).
ilostazol. Addition of cilostazol to aspirin and clopi-
ogrel results in greater ADP-induced platelet inhibition
ompared with dual antiplatelet therapy alone. In a random-
zed trial, Jeong et al. (140) demonstrated that patients with
suboptimal response to dual antiplatelet therapy have
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May 18, 2010:2272–86 Year in Interventional Cardiologyreater platelet inhibition when cilostazol is added com-
ared with aspirin plus clopidogrel 150 mg daily. Triple
ntiplatelet therapy also seemed to improve clinical out-
omes in a nonrandomized study of STEMI patients treated
ith a DES (141).
lycoprotein (GP) IIb/IIIa inhibitors. A wealth of in-
ormation exists regarding the benefits of abciximab during
rimary PCI; however, these studies were conducted before
he widespread use of clopidogrel and the cost constraints of
ur current health care system. Two meta-analyses compar-
ng results of small molecule GP IIb/IIIa inhibitors with
bciximab during primary PCI (142,143) did not demon-
trate any difference in angiographic or clinical outcomes.
he necessity of GP IIb/IIIa may be in question, with more
andomized trials showing lack of benefit of pre-
atheterization administration before (144–147). In pa-
ients who receive GP IIb/IIIa agents, it may be possible to
educe bleeding complications and cost by reducing the
nfusion duration to 2 h (148).
AR-1. Oral SCH 530 548, an oral platelet protease-
ctivated receptor-1 antagonist, was developed to prevent
hrombin-mediated platelet activation. In a trial of 1,030
atients undergoing cardiac catheterization, the agent was
ound to be safe and did not increase risk of TIMI bleeding,
ven when administered with aspirin and clopidogrel (149).
ivalirudin. Mehran et al. (150) published 1-year results of
he HORIZONS AMI (Harmonizing Outcomes with
evascularization and Stents in Acute Myocardial Infarc-
ion) trial. Patients treated with bivalirudin had significantly
mproved outcomes at 1 year compared with those treated
ith heparin plus GP IIb/IIIa inhibitor: net adverse clinical
vents (15.6% vs. 18.3%; p  0.022), major bleeding (5.8%
s. 9.2%; p  0.001), and mortality (3.5% vs. 4.8%; p 
.037).
noxaparin. In a follow-up report from the STEEPLE
Safety and Efficacy of Enoxaparin in Percutaneous Coro-
ary Intervention Patients, an International Randomized
valuation) trial, 1-year survival was similar in patients who
eceived either enoxaparin or unfractionated heparin during
nitial elective PCI (151).
tatins. Statin pretreatment seems to reduce periproce-
ural myocardial injury during PCI. In 668 statin-naïve
atients, a single dose of atorvastatin 80 mg given the day
efore PCI significantly reduced the incidence of MI
ompared with no statin (9.5% vs. 15.8%; p  0.014) (152).
n another trial, Di Sciascio et al. (153) demonstrated that
n atorvastatin reload (80 mg 12 h before PCI; 40 mg
eriprocedural) also improves results in patients receiving
hronic statin therapy, with a significant reduction in
eriprocedural MI (13% vs. 24%; p  0.017) and MACE
3.7% vs. 9.4%; p  0.037). In ACS patients, intensive
tatin (atorvastatin 80 mg) therapy reduced recurrent events
t 30 days compared with moderate-dose statin (pravastatin
0 mg) therapy (154).
ioglitazone. In a small randomized trial of 97 diabetic
atients receiving BMS, pioglitazone was associated with a trend toward a lower in-stent neointimal volume by intra-
ascular ultrasound at 6 months (155).
ontrast Nephropathy
revention. Both short- and long-term prognosis after
CI is markedly impaired if contrast-induced nephropathy
CIN) develops. Jabara et al. (156) point out that the rate of
IN can vary from 3.3% to 10.2% in the same patient
opulation depending on the definition. Currently, the most
requently used definition of CIN is an absolute 0.5 mg/dl
ncrease in creatinine or a 25% increase over baseline. In a
eta-analysis, Brown et al. (157) conclude that hydration
ith combination N-acetylcysteine (NAC) and sodium
icarbonate is the most effective treatment tested in large
opulations. Spargias et al. (158) randomized 208 patients
ith baseline creatinine of more than 1.4 mg/dl to placebo
r infusion of iloprost at 1 ng/kg/min for 4 h. CIN occurred
n 22% of control and 8% of treated patients (p  0.005).
his finding must be replicated in larger trials.
ontrast agents. Controversy still exists regarding whether
ontrast media type influence the development of CIN.
ehran et al. (159) found that with a background of 70%
se of NAC, no difference in incidence of CIN occurred
hen an ionic, low-osmolar agent (ioxaglate) was compared
ith a nonionic agent (iodixanol). In another randomized
rial of 324 patients, there was no difference between
odixanol and iomeprol (160). A meta-analysis of 16 trials
ound that iodixanol was not associated with lower rates of
IN compared with low-osmolar agents (161). This entire
uestion remains clouded in uncertainty. No acceptable
nimal model exists. Most trials are small and underpow-
red. Each trial has differences in hydration strategies; each
ad different background NAC and bicarbonate use. Most
rials that do not specifically test contrast do not standardize
he contrast agent used. Today, optimal preprocedure hy-
ration, NAC pretreatment, and judicious use of total
ontrast volume remains the backbone of preventative ef-
orts to decrease CIN.
eripheral Vascular Disease
enal sympathetic denervation. In a landmark article,
rum et al. (162) presented the results of a study using
adiofrequency catheter-based renal sympathetic denerva-
ion in 50 patients with resistant hypertension (systolic
lood pressure 160 mm Hg with 3 or more medications).
t the 1-year follow-up, there was a substantial and
ustained improvement in blood pressure (approximately
7/13 mm Hg) with no evidence of deterioration in renal
unction. A prospective, randomized trial currently is un-
erway to evaluate this exciting technology further.
enal artery stenting. In a large randomized trial, 806
atients with atherosclerotic renal artery stenosis were
ssigned to undergo renal revascularization plus medical
herapy or to receive medical therapy alone (163). During
he 5-year follow-up, there was no significant difference
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Year in Interventional Cardiology May 18, 2010:2272–86etween the groups in renal function (the primary end
oint, measured by the reciprocal of the serum creatinine
evel), blood pressure, or renal events. These results un-
oubtedly will impact the use of renal revascularization
herapy.
arotid disease. Gray et al. (164) studied 30-day clinical
utcomes among 6,320 high surgical risk patients undergo-
ng carotid artery stenting (CAS) in 2 recent prospective,
ulticenter registries. In patients younger than 80 years of
ge, the incidence of death or stroke was 5.3% for symp-
omatic patients and 2.9% for asymptomatic patients. These
esults demonstrate that CAS outcomes continue to im-
rove and now meet American Heart Association standards
or carotid endarterectomy in both symptomatic (6%) and
symptomatic (3%) lesions.
The role for CAS in patients older than 80 years has been
uestioned. Among 142 elderly patients, Chiam et al. found
more than 85% survival at 2 years, suggesting that CAS is
reasonable strategy in carefully selected patients (165).
uperficial femoral artery disease. In a meta-analysis of
0 trials comparing stenting versus angioplasty for symp-
omatic SFA disease, there was a higher immediate success
ate with stenting, but no difference in restenosis or repeat
evascularization at follow-up (166).
tructural Heart Disease
ortic valve. Transcatheter aortic valve implantation
TAVI) for treatment of calcific aortic stenosis has gener-
ted enormous scientific and public interest. The year 2009
rought much more published information concerning the 2
urrently available valves (Edwards-Sapien, Edwards, Ir-
ine, California; CoreValve device, Medtronic, Minneapo-
is, Minnesota). Clavel et al. (167) carefully analyzed the
emodynamic results of 50 patients with successful Edwards
alve implants compared with a matched control group of
0 patients with surgically implanted bioprosthetic valves.
lthough postoperative gradients were similar, patients
ith small outflows (annulus22 mm) tended to have more
rosthesis–patient mismatch with surgical implants. Con-
ersely, patients with larger annulus sizes (24 mm) tended
o have a higher incidence of paravalvular leak with percu-
aneous aortic valve implantation (PAVI). These data sug-
est that with currently available valve sizes, hemodynamics
s superior with PAVI in smaller annulus dimensions and
uperior with surgical implants in larger annulus sizes.
Himbert et al. (168) described a large French experience
f 75 patients treated with the Edwards-Sapien valve (51
AVI, 24 TAVI). In-hospital mortality was 10%, and the
ncidence of stroke was 4%. One-year survival was 78%. A
efinite learning curve exists: for the first 25 patients, the
-year survival was 60%, compared with 93% for the last 50
atients. This fact has important implications for the
urrent pivotal trial (PARTNER [Placement of Aortic
ranscatheter Valve]) that has completed enrollment in the
.S. The large majority of patients enrolled in PARTNER oere treated in centers with fewer than 25 patients, so this
ivotal randomized trial (that will be definitive for U.S.
DA approval) is basically a trial of the learning curve of a
ew technology compared with a mature surgical approach.
ebb et al. (169) similarly reported outcomes for 168
atients with the Edwards-Sapien valve in Vancouver.
gain, operative mortality fell from 14% in the early
xperience to 8% in the later stage of investigation. In the
AVI group, mortality fell from 12% to 3%, and in the
AVI group, mortality fell from 25% to 11%. Paravalvular
egurgitation was mild and stable over follow-up. At 3 years,
o structural failure of the prosthetic valve occurred. Webb
t al. (170) even more forcefully present the value of center
nd operator experience for this procedure. Here they
escribe their more recent experience in 25 high-risk aortic
tenosis patients with aortic valve area of 0.59  0.15 cm2
ho underwent implantation with a new-generation
dwards-Sapien valve. Successful implantation occurred in
00% and 30-day survival was 100%. Finally, Détaint et al.
171) found that moderate to severe aortic regurgitation
ccurred in 40% of patients treated in the early experience at
heir center, compared with 15% in the later stages of
xperience. Overall, these studies make a strong argument
or centralization of this procedure.
itral valve. Feldman et al. (172) reported long-term
utcomes in 107 patients treated with the Mitraclip device
Evalve, Inc., Menlo Park, California) for symptomatic
itral regurgitation resulting from functional or degenera-
ive disease. Freedom from surgery at 3 years occurred in
6% of patients. In those patients who required surgery,
4% of patients initially eligible for valve repair were able to
ndergo successful valve repair rather than replacement.
his study suggests that the procedure is durable in the
edium term and that surgical correction is not eliminated
s an option if recurrent mitral regurgitation occurs. This
evice is likely to receive FDA approval and will be the first
ommercially available device in the U.S. Sack et al. (173)
nd Schofer et al. (174) reported initial feasibility with novel
oronary sinus mitral annuloplasty devices.
eft atrial appendage occlusion. Previous studies suggest
hat the left atrial appendage (LAA) is the source of emboli
n many patients with atrial fibrillation. For this reason,
ercutaneous occlusion of the LAA has been studied avidly.
olmes et al. (175) describe the Watchman LAA system
or embolic protection. They screened 4,998 patients with
aroxysmal or chronic AF and randomized 707 warfarin-
ligible patients to LAA occlusion and subsequent warfarin
iscontinuation or warfarin. Serious device-related events,
ncluding major bleeding, pericardial effusion, and device
mbolization, were more frequent in the active treatment
roup. The primary efficacy end point was a composite of
eath, stroke, and systemic embolism. LAA occlusion was
oninferior to warfarin therapy. Thus, for patients who can
olerate warfarin, initial device-related complications were
igher, but long-term efficacy in stroke prevention did
ccur. Ideally, clinicians really would like to use this device
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May 18, 2010:2272–86 Year in Interventional Cardiologyn patients at risk of cardiac emboli who cannot tolerate
arfarin. These data are not yet available. Block et al. (176)
lso reported late outcomes of 64 patients treated with
nother LAA occlusion device. At 5 years, the annualized
troke/transient ischemic attack rate was 3.8%/year, which
as less than expected.
atent foramen ovale (PFO). The interventional commu-
ity has been accused of the Sir Edmund Hilary approach to
FO: “Close them because they are there!” In this regard,
he year 2009 brought more discipline to this field. Ford et
l. (177) presented the Mayo Clinic experience with PFO
losure. Between 2001 and 2006, they implanted devices in
52 patients. Indications included 225 patients with cryp-
ogenic stroke and 118 patients with transient ischemic
ttack. Recurrent stroke or transient ischemic attack oc-
urred in 0.9% of patients at 1 year and in 2.8% of patients
t 4 years. Of the 8 patients with recurrent stroke, 5 had
actor V Leiden deficiency, protein C deficiency, or protein
deficiency. This experience suggests excellent efficacy for
econdary prevention and also provides a strong argument
or screening for thrombophilic disorders in these patients.
imilarly, Wahl et al. (178) present the long-term Berne
xperience of 620 patients with PFO closure. They found an
vent-free survival of 97% at the 5-year follow-up. Despite
hese outstanding results, definitive proof of efficacy of PFO
losure for secondary prevention does not exist. For this
eason, O’Gara et al. (179) make an impassioned plea in an
merican Heart Association/American Stroke Association/
merican College of Cardiology Foundation Science Ad-
isory for clinicians to enter their patients into ongoing
ivotal randomized trials.
An even more contentious indication for PFO closure is
igraine prevention. Previously, the MIST trial failed in its
rimary end point of prevention of migraine. Vigna et al.
180) report a systematic evaluation of closure in 82 patients
ith migraine and definite subclinical MRI abnormalities.
mong 52 patients who underwent PFO closure and 29
control) who did not, a 50% reduction in migraine fre-
uency occurred in 87% of the treated patients, whereas
nly 17% of controls demonstrated reduction in migraine
requency (p  0.001). Although the study is limited by its
ize and nonrandomized nature, it is very provocative with
espect to efficacy. More will surely follow!
eprint requests and correspondence: Dr. Simon R. Dixon,
epartment of Cardiovascular Medicine, William Beaumont
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